Skip to main content
Article thumbnail
Location of Repository

GW9662, an antagonist of PPAR-gamma, inhibits breast tumour cell growth and promotes the anticancer effects of the PPAR-gamma agonist Rosiglitazone, independently of PPAR-gamma activation.

By Jason H. Gill, Jill M. Seargent and Elisabeth A. Yates

Abstract

NoPeroxisome proliferator-activated receptor gamma (PPARgamma), a member of the nuclear receptor superfamily, is activated by several compounds, including the thiazolidinediones. In addition to being a therapeutic target for obesity, hypolipidaemia and diabetes, perturbation of PPARgamma signalling is now believed to be a strategy for treatment of several cancers, including breast. Although differential expression of PPARgamma is observed in tumours compared to normal tissues and PPARgamma agonists have been shown to inhibit tumour cell growth and survival, the interdependence of these observations is unclear. This study demonstrated that the potent, irreversible and selective PPARgamma antagonist GW9662 prevented activation of PPARgamma and inhibited growth of human mammary tumour cell lines. Controversially, GW9662 prevented rosiglitazone-mediated PPARgamma activation, but enhanced rather than reversed rosiglitazone-induced growth inhibition. As such, these data support the existence of PPARgamma-independent pathways and question the central belief that PPARgamma ligands mediate their anticancer effects via activation of PPARgamma

Topics: Breast cancer, GW9662, Peroxisome proliferator-activated receptor (PPAR), PPAR¿, Rosiglitazone
Year: 2004
OAI identifier: oai:bradscholars.brad.ac.uk:10454/2987
Provided by: Bradford Scholars
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://hdl.handle.net/10454/29... (external link)
  • http://www3.interscience.wiley... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.